Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
Key Clinical Takeaways
- Design/Population: The ROSELLA trial is a randomized phase 3 study evaluating relacorilant plus nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer. This subgroup analysis focused on patients with prior PARP inhibitor exposure, including those who progressed while receiving PARP inhibition, a population associated with poorer outcomes.
- Key Outcomes: The relacorilant combination demonstrated statistically significant improvements in progression-free survival, with a 44% reduction in recurrence risk among patients who progressed on a PARP inhibitor and a 40% reduction among those previously treated with PARP inhibitors. These results highlight a clinically meaningful benefit specifically among PARP-exposed patients.
- Clinical Relevance: These findings suggest that PARP-inhibitor–exposed patients may derive enhanced benefit from relacorilant plus nab-paclitaxel. Ongoing expansions of the BELLA trial will further explore relacorilant-based combinations in platinum-sensitive ovarian cancer and recurrent endometrial cancer, aiming to broaden therapeutic options for patients with limited effective treatments.
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami, Florida, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
In this subgroup analysis of patients with prior PARP inhibitor exposure, the combination achieved meaningful improvements in progression-free survival, including a 44% reduction in recurrence risk for patients who progressed while on PARP therapy and a 40% reduction for those previously treated with a PARP inhibitor. These results underscore relacorilant’s potential to improve outcomes specifically in PARP-exposed platinum-resistant ovarian cancer.
These findings were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
Source:
Lorusso D, Quesada S, Chan JK, et al. ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor. Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA45
